Is Alibaba Group Holding (BABA) a Smart Long-term Buy?
Alger Spectra Fund recently released its Q3 2020 Investor Letter, a copy of which you can download here. Class A shares of the Alger Spectra Fund outperformed the Russell 3000 Growth Index during the third quarter of 2020. You should check out Alger Spectra Fund’s top 5 stock picks for investors to buy right now, which could be the biggest winners of 2021.
In the Q3 2020 Investor Letter, Alger Spectra Fund Fund highlighted a few stocks and Alibaba Group Holding Limited (NYSE:BABA) is one of them. Alibaba Group Holding Limited (NYSE:BABA) is an e-commerce company. Year-to-date, Alibaba Group Holding Limited (NYSE:BABA) stock gained 11.4% and on December 29th it had a closing price of $236.26. Here is what Alger Spectra Fund said:
Alibaba Increases Share Repurchase Programme thisdaylive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thisdaylive.com Daily Mail and Mail on Sunday newspapers.
Shares of
Alibaba Group Holding Limited (NYSE:BABA) are bouncing back today from a historical sell-off that s seen the Chinese e-commerce titan s stock lose 30% of its value in just two months. As of 10:55 a.m. EST, Alibaba shares are up 6% off of yesterday s multi-month low.
So what
Suffice it to say that this is a curious development on a day when
The Wall Street Journal just reported regulatory risks were extending a Christmas Eve selloff at Alibaba, and described how the canceling of a planned IPO of Alibaba s Ant Group subsidiary and an antimonopoly investigation in China have combined to cost Alibaba $273 billion worth of market cap in just a couple of months. Citing analysts, the
Lead Plaintiff Deadline:
January 12, 2021
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the larger dataset did not provide necessary data regarding aducanumab s effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding aducanumab s effectiveness; (3) the PRIME study did not and would not provide necessary data regarding aducanumab s effectiveness; (4) the data provided by the Company to the FDA s Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all releva